Key facts
- It has raised $6.5M across 3 recorded rounds; the latest was Seed Round ($3.0M) in Jan 2026.
- Notable investors include Agent Capital, Alloy Therapeutics, Tellus BioVentures.
- Cantai Therapeutics has filed 3 Form Ds with the SEC since 2023, most recently Jul 2025 ($550K sold to 3 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Cantai Therapeutics
Funding rounds
3 roundsAbout Cantai Therapeutics
Operator of a therapeutics company intended to advance next-generation bispecific antibodies for autoimmune diseases. The company focuses on treating autoimmune and inflammatory disorders by developing cytokine-targeting, enabling patients suffering from immune-mediated and autoimmune diseases to receive effective treatments.
- Sector
- Healthcare
- HQ
- Philadelphia, PA, United States
- Founded
- 2023
- Employees
- 5
- Website
- cantaitx.com/
- Ownership
- Privately Held (backing)
Cantai Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cantai Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cantai Therapeutics in its N-PORT filings yet. We sweep new filings monthly.